LAUSR

We aim to report the short‐term outcomes of patients undergoing Rezum as a re‐treatment intervention for recurrent lower urinary tract symptoms after prior surgical treatment for benign prostate enlargement. Data from two institutions for baseline International Prostatic Symptom Score with Quality of life item, prostate size, and maximum flow‐rate was acquired. Patients were assessed 3‐month post‐treatment. Outcomes were compared with unpaired t‐tests and Fisher's exact tests. Nineteen patients were included. Prior surgical interventions included transurethral resection of the prostate (31.6%, n = 6), Urolift (26.3%, n = 5), transurethral bladder neck incision (15.8%, n = 3), prostate artery embolization (10.5%, n = 2), transurethral needle ablation, greenlight photovaporization of prostate and Rezum (5.3%, n = 1 each). Median age was 69.0 years (IQR 14; range 59–87 years) with a median prostate volume of 65.0 ml (IQR 63; range 22–160 ml). The median time to Rezum treatment was 48 months (IQR 78; range 9–240 months). 63.1% (n = 12) were re‐started on benign prostatic enlargement medication and 36.8% (n = 7) had recurrent bothersome symptoms before re‐treatment with Rezum. At 3‐month follow up, median International Prostatic Symptom Score decreased from 23 to 9 (p < 0.001) and Quality of life from 4 to 2 (p < 0.001). Median maximum flow‐rate improved after treatment from 8.6 to 14.8 ml/s (p < 0.001). None of the patients were required to restart medication for benign prostate enlargement.